MRD as primary endpoint

Minimal residual disease (MRD) can today be evaluated in individual patient after treatment using various methods with high sensitivity. MRD indicates remaining malignant cells that could be a source of relapse of the disease. Could MRD also be used as an efficient endpoint in the design of new clinical studies?  With help from Professor Ola Landgren, we will look into the crystal ball and discover what the future may hold for MRD.

Host for the podcast is the Swedish hematologist Mats Merup. Special guest in this episode is Ola Landgren, Professor of Medicine, Chief of Myeloma Program & Experimental Therapeutics Program. Sylvester Comprehensive Cancer Center, University of Miami

MAT-BE-2200984 (1.0) 12 2022
Medipodcast

Medipodcast

Biographical Info

You may also be interested in these contents :

Hematology Podcast
Recent findings in MGUS
09/08/2023 
PODCAST
Hematology Podcast
Teaser: The Hematology Podcast
09/08/2023 
PODCAST
Hematology Podcast
AI – The future of pathology?
09/08/2023 
PODCAST

Welcome back !

Login to your account below

Create New Account!

Fill the forms bellow to register

*By registering into our website, you agree to the Terms & Conditions and Privacy Policy.

Retrieve your password

Please enter your username or email address to reset your password.

Add New Playlist

Create New Account!

Fill the form below to register

You already have an account ? Login
-
00:00
00:00
Update Required Flash plugin
-
00:00
00:00